The anti-inflammatory drug hydroxychloroquine should not be used to prevent COVID-19, according to a new recommendation from the World Health Organization.
Numerous clinical studies of more than 6,000 people have shown that the drug had no significant effect on death or hospitalization in people who had not been previously exposed to COVID-19.
Studies have shown “moderate certainty” that hydroxychloroquine not only has no significant effect on laboratory-confirmed COVID-19 infection, but also likely increases the risk of adverse effects.
The WHO recommendation was published at BMJ, a medical journal. A WHO expert group is investigating various drugs that could be used to prevent COVID-1
“The panel believes that this drug is no longer a research priority and that resources should be used to evaluate other more promising drugs to prevent COVID-19,” a WHO statement said.
The recommendations are intended to provide reliable guidelines for the management of COVID-19 and to help physicians make better decisions with their patients, the WHO said.
Hydroxychloroquine was originally approved as an anti-malarial drug and is also used to treat lupus and rheumatoid arthritis.
The drug gained notoriety after the previous one President TrumpDonald Trump Prosecutors focus Trump’s investigation Organization on the company’s CFO: a report by a WHO spokesman says it’s “premature” to think the pandemic will end by the end of the year, Romney has been released from hospital over the weekend MORE, members of his administration and his supporters have constantly promoted it as a miraculous treatment for COVID-19 and as a prophylactic, despite scarce evidence.
Last spring, Trump said he was taking hydroxychloroquine, in combination with zinc, as a way to prevent COVID-19 from being diagnosed with a White House aide.
Trump eventually contracted COVID-19 in October and recovered largely through the use of monoclonal antibody therapy, which was not approved by the Food and Drug Administration at the time.
The popularization by Trump and his allies created a series of drugs that led to a shortage of patients who needed him. Some countries are still trying to cope with the reserves acquired during the height of hydroxychloroquine madness last spring.
The FDA issued an authorization for the emergency use of the drug last March, and outside observers felt the agency was subject to political pressure.
The permit was eventually revoked in June due to serious safety problems. The Agency cites the lack of clinical trials to show that the drug may not be effective in treating or preventing COVID-19 in people who have been exposed, and that the potential benefits do not outweigh the risks.
A separate study by the National Institutes of Health found that hydroxychloroquine was of no benefit to hospitalized patients.